SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001634432-20-000036
Filing Date
2020-09-18
Accepted
2020-09-18 17:00:30
Documents
18
Period of Report
2020-09-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sbbp-20200916x8k.htm   iXBRL 8-K 58455
2 EX-1.1 sbbp-20200916ex11ce4c54e.htm EX-1.1 347679
3 EX-5.1 sbbp-20200916ex51d801ccd.htm EX-5.1 85285
4 EX-99.1 sbbp-20200916ex991b7e22e.htm EX-99.1 11588
5 EX-99.2 sbbp-20200916ex99237577e.htm EX-99.2 15261
6 GRAPHIC sbbp-20200916ex991b7e22e001.jpg GRAPHIC 4901
7 GRAPHIC sbbp-20200916ex99237577e001.jpg GRAPHIC 4901
  Complete submission text file 0001634432-20-000036.txt   753368

Data Files

Seq Description Document Type Size
8 EX-101.SCH sbbp-20200916.xsd EX-101.SCH 3002
9 EX-101.LAB sbbp-20200916_lab.xml EX-101.LAB 16709
10 EX-101.PRE sbbp-20200916_pre.xml EX-101.PRE 10790
11 EXTRACTED XBRL INSTANCE DOCUMENT sbbp-20200916x8k_htm.xml XML 5055
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

IRS No.: 981130690 | State of Incorp.: L2
Type: 8-K | Act: 34 | File No.: 001-37569 | Film No.: 201184540
SIC: 2834 Pharmaceutical Preparations